These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 28447953)

  • 21. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?
    Pradat P; Pugliese P; Poizot-Martin I; Valantin MA; Cuzin L; Reynes J; Billaud E; Huleux T; Bani-Sadr F; Rey D; Frésard A; Jacomet C; Duvivier C; Cheret A; Hustache-Mathieu L; Hoen B; Cabié A; Cotte L;
    J Infect; 2017 Sep; 75(3):234-241. PubMed ID: 28579302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HCV RNA viral load assessments in the era of direct-acting antivirals.
    Cobb B; Pockros PJ; Vilchez RA; Vierling JM
    Am J Gastroenterol; 2013 Apr; 108(4):471-5. PubMed ID: 23552304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No one size fits all-Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection.
    El Sherif O; Afhdal N; Curry M
    J Viral Hepat; 2017 Oct; 24(10):808-813. PubMed ID: 28581634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals.
    Rockstroh JK
    Liver Int; 2015 Jan; 35 Suppl 1():51-5. PubMed ID: 25529087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.
    Li T; Qu Y; Guo Y; Wang Y; Wang L
    Liver Int; 2017 Jul; 37(7):974-981. PubMed ID: 27943605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C virus genotypes in Myanmar.
    Win NN; Kanda T; Nakamoto S; Yokosuka O; Shirasawa H
    World J Gastroenterol; 2016 Jul; 22(27):6095-9. PubMed ID: 27468202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of the activity of directly acting antivirals and other products against different genotypes of hepatitis C virus prevalent in resource-poor countries.
    Khan H; Paeshuyse J; Murad S; Neyts J
    Antiviral Res; 2016 Jan; 125():43-5. PubMed ID: 26593977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical relevance of HCV antiviral drug resistance.
    Welsch C; Zeuzem S
    Curr Opin Virol; 2012 Oct; 2(5):651-5. PubMed ID: 23006585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus.
    Hamana A; Takahashi Y; Uchida T; Nishikawa M; Imamura M; Chayama K; Takakura Y
    Antiviral Res; 2017 Oct; 146():130-138. PubMed ID: 28864074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of hepatitis C patients with decompensated liver disease.
    Hsu CS; Kao JH
    Expert Rev Gastroenterol Hepatol; 2016 Jun; 10(6):679-88. PubMed ID: 26782619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perspectives on dual hepatitis B and C infection in Taiwan.
    Liu CJ; Chen PJ; Chen DS; Tseng TC; Kao JH
    J Formos Med Assoc; 2016 May; 115(5):298-305. PubMed ID: 26188762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C Virus: Viral Quasispecies and Genotypes.
    Tsukiyama-Kohara K; Kohara M
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29271914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic Hepatitis C and Direct Acting Antivirals.
    Westerhoff M; Ahn J
    Surg Pathol Clin; 2018 Jun; 11(2):287-296. PubMed ID: 29751875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Direct-Acting Antivirals Compared with Older Agents for Hepatitis C.
    Ta K; Zehtabchi S
    Am Fam Physician; 2017 Jun; 95(11):Online. PubMed ID: 28671433
    [No Abstract]   [Full Text] [Related]  

  • 35. Direct-acting agents for hepatitis C virus before and after liver transplantation.
    Sugawara Y; Hibi T
    Biosci Trends; 2018 Jan; 11(6):606-611. PubMed ID: 29238003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrosing Cholestatic Hepatitis C After Liver Transplantation: Therapeutic Options Before and After Introduction of Direct-Acting Antivirals: Our Experience and Literature Review.
    Tronina O; Ślubowska K; Mikołajczyk-Korniak N; Komuda-Leszek E; Wieczorek-Godlewska R; Łągiewska B; Pacholczyk M; Lisik W; Kosieradzki M; Durlik M
    Transplant Proc; 2017; 49(6):1409-1418. PubMed ID: 28736015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural Changes In Cells Imaged by Soft X-ray Cryo-Tomography During Hepatitis C Virus Infection.
    Pérez-Berná AJ; Rodríguez MJ; Chichón FJ; Friesland MF; Sorrentino A; Carrascosa JL; Pereiro E; Gastaminza P
    ACS Nano; 2016 Jul; 10(7):6597-611. PubMed ID: 27328170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review.
    Lampejo T; Agarwal K; Carey I
    Dig Liver Dis; 2018 Feb; 50(2):113-123. PubMed ID: 29233687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Caution with the use of the new direct acting antivirals in the hepatitis C virus related renal disease.
    Gomis A; Díaz M; de Lorenzo A; Ruiz-Roso G; Liaño F
    Nefrologia; 2016; 36(6):713-715. PubMed ID: 27575928
    [No Abstract]   [Full Text] [Related]  

  • 40. Entry inhibitors and future treatment of hepatitis C.
    Fofana I; Jilg N; Chung RT; Baumert TF
    Antiviral Res; 2014 Apr; 104():136-42. PubMed ID: 24525381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.